BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $294 | -20.3% | 41,497 | -20.8% | 0.02% | -24.1% |
| Q2 2023 | $369 | -5.1% | 52,423 | +12.5% | 0.03% | +3.6% |
| Q1 2023 | $389 | -15.8% | 46,585 | +15.7% | 0.03% | -26.3% |
| Q4 2022 | $462 | -99.9% | 40,255 | +13.7% | 0.04% | -9.5% |
| Q3 2022 | $446,000 | -5.1% | 35,417 | -20.2% | 0.04% | -2.3% |
| Q2 2022 | $470,000 | +73.4% | 44,408 | +166.9% | 0.04% | +377.8% |
| Q1 2022 | $271,000 | +31.6% | 16,641 | +11.8% | 0.01% | +28.6% |
| Q4 2021 | $206,000 | +26.4% | 14,885 | +31.2% | 0.01% | 0.0% |
| Q3 2021 | $163,000 | +45.5% | 11,349 | +3.5% | 0.01% | -22.2% |
| Q1 2021 | $112,000 | – | 10,970 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |